Laurus Labs Limited vs Speciality Medicines Ltd
A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Speciality Medicines Ltd (SPML) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Speciality Medicines Ltd leads LAURUSLABS vs SPML on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability13
- Growth02
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SPML takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
SPML takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
LAURUSLABS takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + []
- − ["Stock is trading at 20.99 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
- + ["Company is almost debt free.", "Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "Tax rate seems low"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.